Nano-X Imaging Ltd.

Nano-X Imaging Ltd. reported Q1 2026 revenue of $4.3 million, an increase from $2.8 million in Q1 2025, but its GAAP net loss widened to $14.3 million. The company withdrew its 2026 revenue target and will no longer provide annual guidance due to variability in deployment timelines and revenue recognition. Management raised substantial doubt about its ability to continue as a going concern, citing insufficient cash for operations beyond one year. Additionally, a class action lawsuit was filed on June 12, 2026, alleging federal securities law violations.

Nanox announced it will report its financial results for the first quarter ended March 31, 2026, before market open on Thursday, June 25, 2026. The company will host a conference call at 8:30 a.m. ET on the same day, featuring CEO Erez Meltzer and CFO Ran Daniel, to discuss these results and provide a business update. Interested parties can register for the call or access the live webcast through links provided in the announcement.

Nano-X Imaging Ltd. announced that its U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with NuvioDx LLC. This partnership aims to support the deployment of Nanox.ARC multi-source digital tomosynthesis systems across clinical sites in various U.S. states. The agreement strengthens Nanox's commercialization strategy and expands its channel partner network, leveraging NuvioDx's experience in medical imaging technology adoption.

Nano-X Imaging Ltd.'s U.S. subsidiary, Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems. This partnership will facilitate the commercial rollout of Nanox's FDA-cleared Nanox.ARC systems across the U.S. The collaboration aims to broaden access to advanced 3D imaging solutions in various clinical settings, including oncology-adjacent care environments, leveraging the partner's established network.

Nano-X Imaging Ltd. announced that its Nanox.ARC X 3D digital tomosynthesis system has been awarded a Red Dot Award: Product Design 2026. This prestigious recognition highlights the system's exceptional design, which aims to expand access to advanced imaging by enabling deployment in a wider range of clinical settings due to its compact size and ease of installation. CEO Erez Meltzer emphasized that good design is fundamental to broader adoption and improving patient access to essential medical imaging. The Nanox.ARC X, built on proprietary digital X-ray technology, will gain global visibility through features in the Red Dot Design Yearbook and museums.

Nano-X Imaging Ltd. announced a clinical collaboration with Meir Medical Center, part of Israel's largest healthcare organization, to enhance and expand the clinical validation of its Nanox.ARC system. The study will assess the diagnostic value of Nanox.ARC for orthopedic injuries in emergency departments, comparing it against existing diagnostic workflows. The collaboration aims to demonstrate improved anatomical detail, diagnostic confidence, faster clinical decision-making, and lower radiation doses, supporting broader adoption of the 3D imaging technology.

Nano-X Imaging Ltd. announced its U.S. subsidiary, Nanox Impact Inc., signed a distribution agreement with Digital X-Ray Imaging Inc. (DXI) for its FDA-cleared Nanox.ARC system in Arkansas. This marks the fourth U.S. distribution collaboration in 2026, aiming to expand the adoption of digital tomosynthesis. DXI will market, install, and support the Nanox.ARC across its network, leveraging its three decades of experience and strong relationships in the region.